Latest news - Novo Nordisk
Dec 15, 2024 · Novo Nordisk invests DKK 8.5 billion in new production facility in Odense, Denmark
Novo Nordisk shares plunge after CagriSema obesity drug trial …
Dec 20, 2024 · LONDON/COPENHAGEN (Reuters) -Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125...
Compounded semaglutide associated with at least 10 deaths, Novo Nordisk …
Nov 6, 2024 · Novo Nordisk said the data on 10 deaths and more than 100 hospitalizations came from the US Food and Drug Administration’s adverse event reporting database for semaglutide; the FDA warns that ...
Company announcements & press releases - Novo Nordisk
Novo Nordisk A/S Novo Alle 1 2880 Bagsværd Denmark +45-4444-8888 CVR-no. 24256790 Our medicines are for the approved indication for which they are authorised in the local country or region.
Novo Nordisk says it is gradually phasing out human insulin pens ...
Nov 14, 2024 · Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp up manufacturing of its popular obesity and diabetes injections.
Novo Nordisk strikes $11bn deal to expand production of weight …
Feb 5, 2024 · Novo Nordisk has agreed to acquire three manufacturing sites for $11bn, as the Danish drugmaker races to expand production of the weight loss drugs whose runaway success has sent the company’s...
Novo Nordisk Reports Headline Results From Part 1 Of ESSENCE …
Nov 1, 2024 · (RTTNews) - Novo Nordisk (NVO) announced the headline results from part 1 of the ongoing ESSENCE trial, a phase 3, 240-week, double-blinded trial in 1,200 adults with metabolic dysfunction ...
News & media - Novo Nordisk
Get an overview of the Novo Nordisk press releases here or subscribe to our news and get it directly in your mailbox when we have news to tell. Disease areas Science & technology
Novo Nordisk shares plunge 20% after disappointing trial results; …
Dec 20, 2024 · Shares of Danish pharmaceutical giant Novo Nordisk plummeted roughly 20% on Friday after reporting results in a late-stage trial for its experimental CagriSema weight loss drug that missed ...
Novo Nordisk shares tumble as data on weight-loss drug trial …
Dec 20, 2024 · Novo Nordisk and Eli Lilly are competing for dominance in a market that grew sevenfold in just three years to $24bn in 2023, according to data analytics firm Iqvia.